Spin-On Glass: Materials and Applications in Advanced IC Technologies

This thesis deals with the study of shallow PN junction formation by dopant diffusion from Spin-On Glass (SOG) for future deep sub-micron BiCMOS technology. With the advantages of no transient enhanced diffusion and no metal contamination, diffusion from highly doped SOG (also called spin-on dopant - SOD) is a good technology for shallow junction formation. In this thesis, diffusion of impurities from SOD into Si and polysilicon on silicon structure has been studied. This shallow junction formation technique using SOD has been applied in realisation of two important devices, i.e. high frequency bipolar transistor and deep sub-micron elevated source/drain MOSFET

Oxidation of benzyl alcohol to benzaldehyde over MnOx/sepiolite catalysts

MnOx/sepiolite catalysts were synthesized by precipitation method accompanied by the calcination at 4100C. The prepated solids have been characterized by XRD, SEM, TPR-H2. MnOx particles were deposited on the surface of the sepiolite fibers and act as active sites for  the oxidation of benzyl alcohol using tert-butyl hydroperoxide (TBHP) as an oxidizing agent. The catalysts showed a good conversion of benzyl alcohol to benzaldehyde at 60 oC. The influence of the reaction time and reaction temperature was considered. Keywords. MnOx/sepiolite, oxidation, benzyl alcohol conversion, TBHP, benzaldehyde

Low birth weight of Vietnamese infants is related to their mother’s dioxin and glucocorticoid levels

We aimed to determine the relationship between dioxin congeners in maternal breast milk and maternal glucocorticoid levels with newborn birth weight after nearly 45 years of use of herbicides in the Vietnam War. The study subjects comprised 58 mother–infant pairs in a region with high dioxin levels in the soil (hotspot) and 62 pairs from a control region. Dioxin levels in maternal breast milk were measured by HRGC-HRMS. Salivary glucocorticoid levels were determined by LC-MS/MS. Dioxin congener levels in mothers from the hotspot were found to be two to fivefold higher than those in mothers from the control region. Birth weight was inversely correlated with 2,3,7,8-TeCDD and 2,3,4,7,8-PeCDF congener levels. The rate of newborns whose birth weight was less than 2500 g was threefold higher in the hotspot (12 %) than in the control region (4 %). Salivary glucocorticoid levels in mothers with low birth weight infants were significantly higher than those in the normal birth weight group. Low birth weight of Vietnamese newborns in a hotspot for dioxin levels is related to some dioxin congener levels and high glucocorticoid levels in mothers. This finding in mother–infant pairs suggests that excess maternal glucocorticoid levels are related to dioxin burden and they result in low birth weight. © 2016 Springer-Verlag Berlin HeidelbergEmbargo Period 12 month

Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial

Background Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to show if daily oral fluoxetine for 6 months after stroke improves functional outcome in an ethnically diverse population. Methods AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial done in 43 hospital stroke units in Australia (n=29), New Zealand (four), and Vietnam (ten). Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke in the previous 2–15 days, brain imaging consistent with ischaemic or haemorrhagic stroke, and a persisting neurological deficit that produced a modified Rankin Scale (mRS) score of 1 or more. Patients were randomly assigned 1:1 via a web-based system using a minimisation algorithm to once daily, oral fluoxetine 20 mg capsules or matching placebo for 6 months. Patients, carers, investigators, and outcome assessors were masked to the treatment allocation. The primary outcome was functional status, measured by the mRS, at 6 months. The primary analysis was an ordinal logistic regression of the mRS at 6 months, adjusted for minimisation variables. Primary and safety analyses were done according to the patient's treatment allocation. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611000774921. Findings Between Jan 11, 2013, and June 30, 2019, 1280 patients were recruited in Australia (n=532), New Zealand (n=42), and Vietnam (n=706), of whom 642 were randomly assigned to fluoxetine and 638 were randomly assigned to placebo. Mean duration of trial treatment was 167 days (SD 48·1). At 6 months, mRS data were available in 624 (97%) patients in the fluoxetine group and 632 (99%) in the placebo group. The distribution of mRS categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio 0·94, 95% CI 0·76–1·15; p=0·53). Compared with patients in the placebo group, patients in the fluoxetine group had more falls (20 [3%] vs seven [1%]; p=0·018), bone fractures (19 [3%] vs six [1%]; p=0·014), and epileptic seizures (ten [2%] vs two [<1%]; p=0·038) at 6 months. Interpretation Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures. These results do not support the use of fluoxetine to improve functional outcome after stroke